{"title":"Current status and advances in the treatment of colorectal cancer with liver metastases.","authors":"Wei-Xing Liu, Chuang Jiang, Jia-Xin Li","doi":"10.5306/wjco.v16.i7.107438","DOIUrl":null,"url":null,"abstract":"<p><p>The incidence of colorectal cancer is gradually increasing, and a majority of patients are diagnosed with distant metastases at the time of initial diagnosis, with the liver being the most common site of metastasis. Unlike most malignant tumors, patients with distant metastases can still achieve favorable prognoses if both the primary tumor and liver metastases are surgically resected. With advances in systemic therapies, many patients with initially unresectable liver metastases from colorectal cancer can undergo systemic treatment to achieve conversion therapy, thereby gaining the opportunity for surgery. However, there is still no consensus on several issues, including the timing of systemic therapy before and after surgery, whether neoadjuvant therapy should be employed, and the choice between simultaneous or staged surgeries. This review aims to systematically describe the current treatment landscape for colorectal cancer with liver metastases and highlight several unresolved controversial issues, providing valuable insights for the diagnosis and treatment of colorectal liver metastases.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107438"},"PeriodicalIF":3.2000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305101/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i7.107438","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The incidence of colorectal cancer is gradually increasing, and a majority of patients are diagnosed with distant metastases at the time of initial diagnosis, with the liver being the most common site of metastasis. Unlike most malignant tumors, patients with distant metastases can still achieve favorable prognoses if both the primary tumor and liver metastases are surgically resected. With advances in systemic therapies, many patients with initially unresectable liver metastases from colorectal cancer can undergo systemic treatment to achieve conversion therapy, thereby gaining the opportunity for surgery. However, there is still no consensus on several issues, including the timing of systemic therapy before and after surgery, whether neoadjuvant therapy should be employed, and the choice between simultaneous or staged surgeries. This review aims to systematically describe the current treatment landscape for colorectal cancer with liver metastases and highlight several unresolved controversial issues, providing valuable insights for the diagnosis and treatment of colorectal liver metastases.
期刊介绍:
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.